ICON PLC – FDA 483, Oct 24, 2025

An FDA inspection of ICON plc's bioanalytical facility in Assen, Drenthe, Netherlands, resulted in the issuance of a Form FDA 483 on October 24, 2025. The inspection identified a significant observation concerning the company's method validation activities. The primary issue cited was the inadequate evaluation of method specificity for certain bioanalytical methods. Specifically, the facility failed to assess the method's ability to distinguish between the target analyte and potential interfering substances, particularly co-administered medications given to study subjects. While the method's specificity was evaluated in the presence of paracetamol, it was not tested against other drugs that some subjects received, including cetirizine, desogestrel, ethinyl estradiol, drospirenone, ethinylestradiol betadex clathrate, levonorgestrel, and medroxyprogesterone acetate. This oversight means that potential interferences from these additional medications were not considered during the validation process, raising concerns about the reliability of the analytical results. These observations were reported pursuant to Section 704(b) of the Federal Food, Drug and Cosmetic Act, highlighting conditions or practices that require attention to ensure compliance. ICON plc is expected to address these findings by discussing any objections or submitting proposed corrective actions to the FDA. The resolution of this observation is critical for ensuring the integrity and accuracy of their bioanalytical services.